Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The proportion of patients receiving vitamin D supplementation for more than 3 months was similar in both cohorts (Table 1).The flowchart illustrates the study selection process, including all exclusion criteria from screening and enrollment to the final number of participants.Characteristics of BoHemE study participants.Controls(n = 84)MDS cohort(n = 111)Sex, n Women46 (55%)40 (36%) Men38 (45%)71 (64%)Age, years All68 (63 to 75)68 (65 to 73) Women69 (63 to 76)68 (64 to 73) Men68 (64 to 73)69 (65 to 73)BMI, [kg/m2] All27.8 (25.6 to 32.4)26.6 (24.2 to 28.2)** Women26.6 (23.9 to 28.1)25.8 (23.6 to 27.6) Men29.4 (27.8 to 34.2)27.0 (24.6 to 29.4)****T-score All−1.0 (−1.8 to −0.1)−1.2 (−2.0 to −0.5)* Women−1.3 (−1.8 to −0.2)−1.6 (−2.1 to −0.8)* Men−0.8 (−1.5 to 0.1)−1.0 (−1.9 to −0.4)Falls are known, n Yes19 (23%)5 (6%)*** No64 (77%)85 (94%) No information121Fractures are known, n Yes16 (19%)6 (6%)* Vertebral53 Non-vertebral/hip113 Radius fracture4: No67 (81%)87 (94%) No information118Vitamin D supplementation at the time of screening (>3 months) Yes9 (11%)14 (13%) No75 (89%)97 (87%)Diseases and comorbidities, n Cancera8 (10%)17 (15%) Chronic kidney disease1 (1%)5 (5%) Diabetes mellitus12 (14%)18 (16%) Rheumatoid arthritis2 (2%)3 (3%) Thyroid diseases8 (10%)21 (19%)For continuous variables median (1st: 3rd quartile) are given.*p < 0.05, **p < 0.01; ***p < 0.001, ****p < 0.0001 vs. controls.aExcept blood cancer.Classification of the MDS cohort.MDS cohort (n = 111)Time since MDS diagnosis, [months] All13 (4-37) Women11 (4-29) Men18 (5-40)WHO 2022 classification, n MDS-5q5 (4%) MDS-SF3B114 (13%) MDS-biTP532 (2%) MDS-LB27 (24%) MDS-LB and RS3 (3%) MDS-h1 (1%) MDS-IB44 (40%) MDS-f: CMML15 (13%)IPSS-M risk group, na Very low5 (5%) Low30 (31%) Moderate low17 (18%) Moderate high10 (11%) High19 (20%) Very high14 (15%)Transfusion-dependent, n Yes33 (30%) No78 (70%)WHO World Health Organization, MDS-5q MDS with low blasts and isolated 5q deletion, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-biTP53 MDS with biallelic TP53 inactivation, MDS-LB and RS MDS with low blasts and ring sideroblast, MDS-LB MDS with low blasts, MDS-IB MDS with increased blasts-1/-2, MDS-h hypoplastic MDS, MDS-f MDS with fibrosis, CMML chronic myelomonocytic leukemia-0/-1/-2, IPSS-M International Prognostic Scoring System-molecular.aWithout patients with CMML and one patient with MDS with VEXAS syndrome.
Source: Baseline characteristics of the study population. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Study design awaiting verification · Leukemia · 2026
Original publication title
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05].
Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05].
The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
Authors’ abstract
Myelodysplastic neoplasms (MDS) are characterized by insufficient hematopoiesis and alterations of the bone marrow microenvironment. However, bone health in MDS has not been evaluated in a prospective, longitudinal setting. Within the Bone and Hematology in Elderly (BoHemE) study, bone mineral density (represented as T-score) and bone-specific serum markers were assessed in patients with MDS (n = 111; 36% female) and age-matched controls (n = 84; 55% female) at baseline and after 3 years. At baseline, patients with MDS had a lower T-score [−0.2; p < 0.05] compared to controls, which was mainly attributed to the lower T-score in women with MDS [−0.3; p < 0.05].
Furthermore, the DNMT3A mutation was associated with a lower T-score within the MDS cohort [−0.7; p < 0.05], but the occurrence in controls had no effect. Albumin-adjusted calcium and phosphate levels correlated with T-scores within the MDS cohort [p < 0.0001 and p < 0.01, respectively], independent of age, sex, MDS duration, IPSS-M score, or transfusion dependence. Quality of life was lower in patients with MDS [p < 0.01], and remained stable over 3 years, whereas T-scores declined [−0.3; p < 0.05].
The presence of osteoporosis was associated with poor overall survival in MDS [p < 0.01]. In conclusion, bone health should be evaluated as part of the diagnostic work-up and clinical management of MDS.
Publication and source details
Original title: Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study
Heike Weidner; Elena Tsourdi; Anne Sophie Platzbecker; Martina Rauner; Ulrike Baschant; Maria G. Ledesma-Colunga; Karolina Basiak; Katja Sockel; Ekaterina Balaian; Susann Winter; Anna Harig; Klaus H. Metzeler; Katharina S. Götze; Dominic Brauer; Nicole Modler; Michael Cross; Marie Schneider; Jörg Lützner; Andreas Roth; Thomas Zerjatke; Gabriele Müller; Uwe Platzbecker; Lorenz C. Hofbauer
Leukemia · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft (German Research Foundation)FerrOs FOR5146µBone SPP-2084µBone SPP-2084FerrOs FOR5146µBone SPP-2084FerrOs FOR5146Weidner Heike Rauner Martina Baschant Ulrike Hofbauer Lorenz C. Deutsches Konsortium für Translationale Krebsforschung (DKTK) CHOICE consortiumGerman Federal Ministry of Research, Technology and Space BMFTR: CAMINO, 01EO2101Deutsches Konsortium für Translationale Krebsforschung (DKTK), CHOICE consortiumRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:32:03.476485+00:00
DOI: 10.1038/s41375-026-03125-8 · PMC13713548